Greenwich LifeSciences (GLSI) Accumulated Expenses (2019 - 2025)
Greenwich LifeSciences (GLSI) posted Accumulated Expenses of $276496.0 for Q4 2025, down 9.72% on a QoQ basis from $306281.0 in Q3 2025, and up 264.21% year-over-year from $75916.0 in Q4 2024.
Greenwich LifeSciences (GLSI) Accumulated Expenses (2019 - 2025) Analysis & Trends
Greenwich LifeSciences' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $276496.0 for Q4 2025.
- Quarterly Accumulated Expenses rose 264.21% year-over-year to $276496.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $276496.0 (up 264.21% YoY) and the FY2025 annual result came in at $276496.0, up 264.21% from the prior year.
- Accumulated Expenses was $276496.0 for Q4 2025 at Greenwich LifeSciences, down from $306281.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $306281.0 in Q3 2025 and bottomed at $1083.0 in Q2 2023.
- A 5-year average of $87631.6 and a median of $65116.5 in 2021 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses tumbled 89.31% — and 2024, when it surged 1543.31%.
- Greenwich LifeSciences' Accumulated Expenses stood at $164327.0 in 2021, then sank by 74.4% to $42060.0 in 2022, then declined by 9.44% to $38089.0 in 2023, then soared by 99.31% to $75916.0 in 2024, then surged by 264.21% to $276496.0 in 2025.
- Business Quant data shows GLSI's Accumulated Expenses at $276496.0 in Q4 2025, $306281.0 in Q3 2025, and $82852.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 276,496.00 |
| Sep 30, 2025 | 306,281.00 |
| Jun 30, 2025 | 82,852.00 |
| Mar 31, 2025 | 84,362.00 |
| Dec 31, 2024 | 75,916.00 |
| Sep 30, 2024 | 67,625.00 |
| Jun 30, 2024 | 17,797.00 |
| Mar 31, 2024 | 220,845.00 |
| Dec 31, 2023 | 38,089.00 |
| Sep 30, 2023 | 66,385.00 |
| Jun 30, 2023 | 1,083.00 |
| Mar 31, 2023 | 14,730.00 |
| Dec 31, 2022 | 42,060.00 |
| Sep 30, 2022 | 17,034.00 |
| Jun 30, 2022 | 8,289.00 |
| Mar 31, 2022 | 20,323.00 |
| Dec 31, 2021 | 164,327.00 |
| Sep 30, 2021 | 159,274.00 |
| Jun 30, 2021 | 25,017.00 |
| Mar 31, 2021 | 63,848.00 |